DNA demethylating therapy in MDS:: The experience with 5-AZA-2′-deoxycytidine (decitabine).

被引：0
|
作者：
Wijermans, P
Luebbert, M
Verhoef, G
Bosly, A
Ravoet, C
Andre, M
Ferrant, A
Haak, H
机构：
[1] Leyenburg Hosp, Dept Haematol, The Hague, Netherlands
[2] Univ Freiburg, Freiburg, Germany
[3] Univ Grootgasthuisberg, Louvain, Belgium
[4] Mt Godinne UCL, Yvoir, Belgium
[5] Hosp Jolimont, Haine St Paul, Belgium
[6] Hosp Notre Dame, Charleroi, Belgium
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1368
引用
收藏
页码：306A / 306A
页数：1
相关论文
共 50 条
  • [21] 5-AZA-2'-DEOXYCYTIDINE (DAC) - THE EUROPEAN-EXPERIENCE
    DODION, P
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 68 - 68
  • [22] The Demethylating Agent 5-Aza-2′-Deoxycytidine (5-AZA-CdR) Inhibits The Development of Preimplantation Mouse Embryos
    Yu Jian-Ning
    Li Shao-Hua
    Wang Dan-Qiu
    Wang Meng
    Lin Fen
    Liu Hong-Lin
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2009, 36 (02) : 228 - 237
  • [23] 5-AZA-2'-DEOXYCYTIDINE (DECITABINE) INDUCES TRILINEAGE RESPONSE IN UNFAVORABLE MYELODYSPLASTIC SYNDROMES
    ZAGONEL, V
    LORE, G
    MAROTTA, G
    BABARE, R
    SARDEO, G
    GATTEI, V
    DEANGELIS, V
    MONFARDINI, S
    PINTO, A
    LEUKEMIA, 1993, 7 : 30 - 35
  • [24] Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update
    Joeckel, Tina E.
    Luebbert, Michael
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 330 - 341
  • [25] Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel
    Shang, Donghao
    Ito, Norlyuki
    Kamoto, Toshlyuki
    Ogawa, Osamu
    UROLOGY, 2007, 69 (05) : 1007 - 1012
  • [26] Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma
    Hirasawa, Yuichi
    Arai, Makoto
    Imazeki, Fumio
    Tada, Motohisa
    Mikata, Rintaro
    Fukai, Kenichi
    Miyazaki, Masaru
    Ochiai, Takenori
    Saisho, Hiromitsu
    Yokosuka, Osamu
    ONCOLOGY, 2006, 71 (1-2) : 77 - 85
  • [27] 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies:: a multimechanism therapeutic approach?
    Sigalotti, L
    Altomonte, M
    Colizzi, F
    Degan, M
    Rupolo, M
    Zagonel, V
    Pinto, A
    Gattei, V
    Maio, M
    BLOOD, 2003, 101 (11) : 4644 - 4645
  • [28] Epigenetic therapy of non-small cell ung cancer using decitabine (5-aza-2'-deoxycytidine)
    Momparler, Richard L.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [29] DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia
    Yang, Allen S.
    Doshi, Ketan D.
    Choi, Sang-Woon
    Mason, Joel B.
    Mannari, Rajan K.
    Gharybian, Vazganush
    Luna, Rene
    Rashid, Asif
    Shen, Lanlan
    Estecio, Marcos R. H.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Issa, Jean-Pierre J.
    CANCER RESEARCH, 2006, 66 (10) : 5495 - 5503
  • [30] Inhibition of DNA methylation by continuous infusion of 5-Aza-2′-Deoxycytidine (Decitabine):: A phase I study with molecular goals
    Leachman, S
    Jones, D
    Karpf, A
    Florell, S
    Porter-Gill, P
    Wheeler, R
    Samlowsk, W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 538 - 538
12345